modafinil has been researched along with Local Neoplasm Recurrence in 3 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results suggest a subset of ovarian cancer patients with enhanced susceptibility to Vigil immunotherapy." | 3.11 | Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. ( Aaron, P; Bognar, E; Choucair, K; Morand, S; Nemunaitis, J; Robinson, M; Sliheet, E; Stanbery, L; Willoughby, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sliheet, E | 1 |
| Robinson, M | 1 |
| Morand, S | 1 |
| Choucair, K | 1 |
| Willoughby, D | 1 |
| Stanbery, L | 3 |
| Aaron, P | 2 |
| Bognar, E | 3 |
| Nemunaitis, J | 3 |
| Anderson, P | 1 |
| Ghisoli, M | 1 |
| Crompton, BD | 1 |
| Klega, KS | 1 |
| Wexler, LH | 1 |
| Slotkin, EK | 1 |
| Manning, L | 2 |
| Wallraven, G | 2 |
| Manley, M | 2 |
| Horvath, S | 2 |
| Rocconi, RP | 1 |
| Stevens, EE | 1 |
| Bottsford-Miller, JN | 1 |
| Ghamande, SA | 1 |
| Elder, J | 1 |
| DeMars, LL | 1 |
| Munkarah, A | 1 |
| Walter, A | 1 |
| Galanis, E | 1 |
| Herzog, T | 1 |
| Monk, BJ | 1 |
| Coleman, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)[NCT03073525] | Phase 2 | 25 participants (Actual) | Interventional | 2017-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
OS is defined as time of randomization to date of death due to any cause. (NCT03073525)
Timeframe: OS will be evaluated from time of randomization up to 37 months following documented disease progression.
| Intervention | Months (Median) |
|---|---|
| Part 1: Vigil + Atezo | 8.2 |
| Part 2: Vigil Then Vigil + Atezo | 37.0 |
| Part 2: Atezo Then Vigil + Atezo | 15.1 |
"Radiographic ORR is defined as the percentage of participants achieving a Complete Response (CR) or Partial Response (PR), as assessed by investigators using RECIST 1.1.~In Part 1, ORR was assessed at baseline and every third cycle thereafter. In Part 2, the disease was assessed at baseline, at the end of Cycle 2 of single-agent therapy, and every third cycle thereafter.~95% confidence interval from exact binomial distribution (Blopper-Pearson method)." (NCT03073525)
Timeframe: From first dose to end of study treatment (up to 9 months)
| Intervention | percentage of participants with response (Number) |
|---|---|
| Part 1: Vigil + Atezo | 33 |
| Part 2: Vigil Then Vigil + Atezo | 9 |
| Part 2: Atezo Then Vigil + Atezo | 10 |
"Overall assessment of time to progression and survival will be measured by Radiological Tumor Assessment by local investigators using the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.~In Part 1, disease progression was assessed at baseline and every third cycle thereafter. In Part 2, the disease was assessed at baseline, at the end of Cycle 2 of single-agent therapy, and every third cycle thereafter." (NCT03073525)
Timeframe: From baseline (prior to treatment) up to 3 years
| Intervention | months (Median) |
|---|---|
| Part 1: Vigil + Atezo | 3.42 |
| Part 2: Vigil Then Vigil + Atezo | 3.42 |
| Part 2: Atezo Then Vigil + Atezo | 2.86 |
The safety evaluation included Adverse Events (AEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs) and changes from baseline in laboratory evaluations, vital signs, electrocardiograms and physical examinations. AEs were graded according to the National Cancer Institute (NCI) CTCAE v4.03 and coded using the Medical Dictionary for Regulatory Activities. Laboratory abnormalities were graded according to the NCI CTCAE v4.03, if applicable. (NCT03073525)
Timeframe: AEs reported from first treatment dose and up to 30 days after last treatment, about 12 months.
| Intervention | adverse events (Number) | |||
|---|---|---|---|---|
| Grade 4 Atezolizumab-Related | Grade 4 Vigil-Related | Grade 3 Atezolizumab-Related | Grade 3 Vigil-Related | |
| Part 1: Vigil + Atezo | 0 | 0 | 0 | 0 |
| Part 2: Atezo Then Vigil + Atezo | 0 | 0 | 4 | 0 |
| Part 2: Vigil Then Vigil + Atezo | 0 | 0 | 1 | 0 |
2 trials available for modafinil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
Topics: BRCA1 Protein; Female; Homologous Recombination; Humans; Immunotherapy; Modafinil; Neoplasm Recurren | 2022 |
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovaria | 2022 |
1 other study available for modafinil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Circulating Tumor DNA; Hum | 2023 |